{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:21:55Z","timestamp":1790835715911,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N34E670096"],"award-info":[{"award-number":["N34E670096"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["HEA_FF_68_059_3000_010"],"award-info":[{"award-number":["HEA_FF_68_059_3000_010"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","award":["3020250020"],"award-info":[{"award-number":["3020250020"]}],"id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.iotech.2026.101584","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:32:22Z","timestamp":1770226342000},"page":"101584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy"],"prefix":"10.1016","volume":"29","author":[{"given":"T.","family":"Inthanachai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9962-1899","authenticated-orcid":false,"given":"C.","family":"Sittplangkoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-1710","authenticated-orcid":false,"given":"H.","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yagyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8734-6626","authenticated-orcid":false,"given":"T.","family":"Palaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2151-4580","authenticated-orcid":false,"given":"S.","family":"Tawinwung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4010-933X","authenticated-orcid":false,"given":"K.","family":"Suppipat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iotech.2026.101584_bib1","series-title":"StatPearls","article-title":"Acute myeloid leukemia","author":"Vakiti","year":"2025"},{"issue":"10393","key":"10.1016\/j.iotech.2026.101584_bib2","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.iotech.2026.101584_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41408-023-00953-0","article-title":"Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure","volume":"13","author":"Mozaffari Jovein","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.iotech.2026.101584_bib4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.iotech.2026.101584_bib5","article-title":"CAR-T cell therapy in hematological malignancies: current opportunities and challenges","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.iotech.2026.101584_bib6","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.iotech.2026.101584_bib7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"issue":"8","key":"10.1016\/j.iotech.2026.101584_bib8","doi-asserted-by":"crossref","first-page":"9655","DOI":"10.1002\/cam4.5916","article-title":"Anti-CLL1-based CAR T-cells with 4-1-BB or CD28\/CD27 stimulatory domains in treating childhood refractory\/relapsed acute myeloid leukemia","volume":"12","author":"Pei","year":"2023","journal-title":"Cancer Med"},{"issue":"suppl 16","key":"10.1016\/j.iotech.2026.101584_bib9","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1200\/JCO.2024.42.16_suppl.6518","article-title":"Phase I study of functionally enhanced CD33 CAR T cells in patients with relapsed or refractory acute myeloid leukemia","volume":"42","author":"Pan","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.iotech.2026.101584_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114260","article-title":"Immunotherapeutic targeting of surfaceome heterogeneity in AML","volume":"43","author":"Bordeleau","year":"2024","journal-title":"Cell Rep"},{"issue":"21","key":"10.1016\/j.iotech.2026.101584_bib11","doi-asserted-by":"crossref","first-page":"10494","DOI":"10.1073\/pnas.1902375116","article-title":"Heterogeneity in refractory acute myeloid leukemia","volume":"116","author":"Horibata","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.iotech.2026.101584_bib12","first-page":"392","article-title":"CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype","volume":"83","author":"Cascavilla","year":"1998","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.iotech.2026.101584_bib13","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood.V78.11.2962.2962","article-title":"Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells","volume":"78","author":"Ikeda","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.iotech.2026.101584_bib14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.omto.2023.07.003","article-title":"Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells","volume":"30","author":"Magnani","year":"2023","journal-title":"Mol Ther Oncolytics"},{"issue":"10","key":"10.1016\/j.iotech.2026.101584_bib15","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41375-020-0818-9","article-title":"Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells","volume":"34","author":"Myburgh","year":"2020","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.iotech.2026.101584_bib16","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1038\/s41375-024-02409-1","article-title":"Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells","volume":"38","author":"Volta","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.iotech.2026.101584_bib17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.exphem.2021.01.003","article-title":"Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells","volume":"95","author":"Russkamp","year":"2021","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1016\/j.iotech.2026.101584_bib18","first-page":"423","article-title":"mRNA-based gene transfer as a tool for gene and cell therapy","volume":"9","author":"Van Tendeloo","year":"2007","journal-title":"Curr Opin Mol Ther"},{"issue":"11","key":"10.1016\/j.iotech.2026.101584_bib19","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol Ther"},{"issue":"7","key":"10.1016\/j.iotech.2026.101584_bib20","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.iotech.2026.101584_bib21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1089\/hum.2018.145","article-title":"Purification of mRNA encoding chimeric antigen receptor is critical for generation of a robust T-cell response","volume":"30","author":"Foster","year":"2019","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.iotech.2026.101584_bib22","article-title":"Twelve-month follow-up of patients with generalized myasthenia gravis receiving BCMA-directed mRNA Cell therapy","author":"Chahin","year":"2024","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.iotech.2026.101584_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010083","article-title":"Novel B7-H3 CAR T cells show potent antitumor effects in glioblastoma: a preclinical study","volume":"13","author":"Inthanachai","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"7","key":"10.1016\/j.iotech.2026.101584_bib24","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","article-title":"A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice","volume":"28","author":"Freyn","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.iotech.2026.101584_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.983000","article-title":"mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model","volume":"13","author":"Sittplangkoon","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.iotech.2026.101584_bib26","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","article-title":"A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA","volume":"15","author":"Baiersdorfer","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"issue":"11","key":"10.1016\/j.iotech.2026.101584_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70055","article-title":"A single-chain variable fragment-based bispecific T-cell activating antibody against CD117 enables T-cell mediated lysis of acute myeloid leukemia and hematopoietic stem and progenitor cells","volume":"8","author":"Volta","year":"2024","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.iotech.2026.101584_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15492-5","article-title":"Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death","volume":"7","author":"Heo","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.iotech.2026.101584_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/biomedicines6010031","article-title":"CD117\/c-kit in cancer stem cell-mediated progression and therapeutic resistance","volume":"6","author":"Foster","year":"2018","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.iotech.2026.101584_bib30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.molcel.2013.12.008","article-title":"RIG-I modulates Src-mediated AKT activation to restrain leukemic stemness","volume":"53","author":"Li","year":"2014","journal-title":"Mol Cell"},{"issue":"5","key":"10.1016\/j.iotech.2026.101584_bib31","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7150\/ijbs.6087","article-title":"The C-kit receptor-mediated signal transduction and tumor-related diseases","volume":"9","author":"Liang","year":"2013","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.iotech.2026.101584_bib32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41467-018-08201-x","article-title":"Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation","volume":"10","author":"Czechowicz","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.iotech.2026.101584_bib33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood-2019-126239","article-title":"Non-genotoxic anti-CD117 antibody conditioning results in successful hematopoietic stem cell engraftment in patients with severe combined immunodeficiency","volume":"134","author":"Agarwal","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.iotech.2026.101584_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exphem.2023.05.001","article-title":"Dynamics of human hematopoietic stem and progenitor cell differentiation to the erythroid lineage","volume":"123","author":"Schippel","year":"2023","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.iotech.2026.101584_bib35","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.3324\/haematol.2018.207811","article-title":"CD117(hi) expression identifies a human fetal hematopoietic stem cell population with high proliferation and self-renewal potential","volume":"105","author":"Maillard","year":"2020","journal-title":"Haematologica"},{"issue":"6656","key":"10.1016\/j.iotech.2026.101584_bib36","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.iotech.2026.101584_bib37","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.3390\/cancers11081198","article-title":"Clinical-scale production of CAR-T cells for the treatment of melanoma patients by mRNA transfection of a CSPG4-specific CAR under full GMP compliance","volume":"11","author":"Wiesinger","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.iotech.2026.101584_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2023.101123","article-title":"Large-scale manufacturing of base-edited chimeric antigen receptor T cells","volume":"31","author":"Woodruff","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"11","key":"10.1016\/j.iotech.2026.101584_bib39","doi-asserted-by":"crossref","first-page":"9181","DOI":"10.3390\/cimb45110576","article-title":"Recruiting in vitro transcribed mRNA against cancer immunotherapy: a contemporary appraisal of the current landscape","volume":"45","author":"Miliotou","year":"2023","journal-title":"Curr Issues Mol Biol"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018826000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:37:34Z","timestamp":1778906254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018826000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"alternative-id":["S2590018826000031"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101584","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transient mRNA-based CD117 CAR T cells effectively target acute myeloid leukemia in vitro for potential use as a preconditioning strategy","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2026.101584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101584"}}